Whereas the present study provides insight into the link between the identified mutations in KCNA5 and the incidence of AF, IKur is also of more general interest as a target for AF management: it is atrial specific [2] and thus provides an attractive prospect for pharmacological intervention because it can be targeted without adverse effects on the ventricles. This evidence concerns the gene KCNA5 and atrial fibrillation.